Cidara, Mundipharma in Partnership to Develop and Commercialize Rezafungin

Collaboration combines strengths to develop and commercialize life-saving antifungal treatment and prophylaxis, an area of high unmet medical need

Mundipharma acquires exclusive rights to develop and commercialize rezafungin in all markets outside of the United States and Japan, which will be retained by Cidara

Cidara to receive upfront payment of $30 million and equity investment of $9 million, co-development funding, development milestones and tiered royalty stream

Total transaction value could exceed $568 million

Cidara to host conference call today at 8:00 a.m. ET/5:00 a.m. PT

https://www.marketscreener.com/CIDARA-THERAPEUTICS-INC-21685642/news/Cidara-Therapeutics-and-Mundipharma-Form-Strategic-Partnership-to-Develop-and-Commercialize-Rezafu-29149651/